inclusion criteria: 1. men and women age 18 and older 2. laboratory-confirmed sars-cov-2 patients who have mild to moderate symptoms related to covid-19 infection and are admitted to community treatment centers in seoul, korea 3. has symptoms consistent with covid-19 with onset ≤7 days of randomization * currently symptomatic with one or more of the following symptoms: fever, cough, myalgia, shortness of breath, nausea, anorexia, diarrhea, vomiting, anosmia (inability to smell), ageusia (inability to taste), sore throat, headache 4. has laboratory-confirmed sars-cov-2 infection (positive rt-pcr test) ≤ 3 days of randomization 5. able to provide informed consent

inclusion criteria: 1. men and women age 18 and older 2. laboratory-confirmed sars-cov-2 patients who have mild to moderate symptoms related to covid-19 infection and are admitted to community treatment centers in seoul, korea 3. has symptoms consistent with covid-19 with onset ≤7 days of randomization * currently symptomatic with one or more of the following symptoms: fever, cough, myalgia, shortness of breath, nausea, anorexia, diarrhea, vomiting, anosmia (inability to smell), ageusia (inability to taste), sore throat, headache 4. has laboratory-confirmed sars-cov-2 infection (positive rt-pcr test) ≤ 3 days of randomization 5. able to provide informed consent

inclusion criteria: men and women age 18 and older laboratory-confirmed sars-cov-2 patients who have mild to moderate symptoms related to covid-19 infection and are admitted to community treatment centers in seoul, korea has symptoms consistent with covid-19 with onset ≤7 days of randomization currently symptomatic with one or more of the following symptoms: fever, cough, myalgia, shortness of breath, nausea, anorexia, diarrhea, vomiting, anosmia (inability to smell), ageusia (inability to taste), sore throat, headache has laboratory-confirmed sars-cov-2 infection (positive rt-pcr test) ≤ 3 days of randomization able to provide informed consent

inclusion criteria: men and women age 18 and older laboratory-confirmed sars-cov-2 patients who have mild to moderate symptoms related to covid-19 infection and are admitted to community treatment centers in seoul, korea has symptoms consistent with covid-19 with onset ≤7 days of randomization currently symptomatic with one or more of the following symptoms: fever, cough, myalgia, shortness of breath, nausea, anorexia, diarrhea, vomiting, anosmia (inability to smell), ageusia (inability to taste), sore throat, headache has laboratory-confirmed sars-cov-2 infection (positive rt-pcr test) ≤ 3 days of randomization able to provide informed consent

inclusion criteria: 1. men and women age 18 and older 2. laboratory-confirmed sars-cov-2 patients who have mild to moderate symptoms related to covid-19 infection and are admitted to community treatment centers in seoul, korea 3. has symptoms consistent with covid-19 with onset ≤7 days of randomization - currently symptomatic with one or more of the following symptoms: fever, cough, myalgia, shortness of breath, nausea, anorexia, diarrhea, vomiting, anosmia (inability to smell), ageusia (inability to taste), sore throat, headache 4. has laboratory-confirmed sars-cov-2 infection (positive rt-pcr test) ≤ 3 days of randomization 5. able to provide informed consent

inclusion criteria: 1. men and women age 18 and older 2. laboratory-confirmed sars-cov-2 patients who have mild to moderate symptoms related to covid-19 infection and are admitted to community treatment centers in seoul, korea 3. has symptoms consistent with covid-19 with onset ≤7 days of randomization - currently symptomatic with one or more of the following symptoms: fever, cough, myalgia, shortness of breath, nausea, anorexia, diarrhea, vomiting, anosmia (inability to smell), ageusia (inability to taste), sore throat, headache 4. has laboratory-confirmed sars-cov-2 infection (positive rt-pcr test) ≤ 3 days of randomization 5. able to provide informed consent